TNF and Insulin resistance: Non-clinical studies have shown that azilsartan increases the expression of PPARγ and decreases that of tumor necrosis factor-α (TNF-α), a cytokine that reduces insulin sensitivity; therefore, it is expected to improve insulin resistance in clinical settings [14–16].